Investigating Radioprotective Effect of Hesperidin/Diosmin Compound Against ^99mTc-MIBI-Induced Cardiotoxicity: Animal...

This study was designed to indicate the cardiotoxicity due to ^99mTc-MIBI injection in myocardial perfusion imaging in wistar Rats. In addition, protective effect of hesperidin/diosmin compound (HDC) against the cardiotoxicity was evaluated. Twenty five male rats were randomly divided into five groups. The rats in Group 1 (control) only received PBS. For Group 2 (HDC only) the rats treated with only HDC. The rats in Group 3 (radiation) received PBS before injection and exposure to 1 mCi ^99mTc-MIBI. The rats in Group 4 (HDC + radiation) treated with HDC before exposure. For Group 5 (radiation + HDC) the rats were exposed and thereafter administered HDC. The Animals of this study were orally administered 100 mg/kg/day of the HDC for 7 days. Then, the rats were sacrificed and afterwards their heart tissues were carefully extracted for biochemical and histopathological evaluations. According to our results in the radiation group, the rate of rupture of cardiomyocyte fibers was higher than other groups, and in some fibers, the presence of lymphocytes was observed. Relative improvement was observed in radiation + HDC group compared to the radiation group and also a small number of cardiomyocyte fibers were torn and in some fibers, the presence of lymphocytes was observed, which was less than the model group. Collagen deposition significantly increased in radiation group compared to control group (P < 0.05). It can be seen that the percentage of collagen deposition decreased substantially in the group treated with HDC before or after radiation compared to radiation group (P < 0.05). The MDA activities significantly reduced (P < 0.05) in both (HDC + radiation) and (radiation + HDC) groups. SOD activity significantly increased in both (radiation + HDC) and (HDC + radiation) groups compared to that of radiation group (P < 0.05). It could be concluded that the HDC is safe and promising useful therapeutic agent in radiation induced cardiotoxicity for patients undergoing nuclear medicine procedures.